- Home
- MGTX vs PRME Comparison
MGTX vs PRME Comparison
Compare MGTX & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | PRME |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 610.1M | 666.1M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | MGTX | PRME |
|---|---|---|
| Price | $9.51 | $3.42 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $22.86 | $7.56 |
| AVG Volume (30 Days) | 581.0K | ★ 2.2M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.02 | 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $81,391,000.00 | $4,632,000.00 |
| Revenue This Year | $118.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 144.57 | 55.28 |
| 52 Week Low | $4.73 | $1.11 |
| 52 Week High | $9.88 | $6.94 |
Technical Indicators
Market Signals| Indicator | MGTX | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 72.36 | 43.35 |
| Support Level | $7.19 | $3.17 |
| Resistance Level | N/A | $3.94 |
| Average True Range (ATR) | 0.53 | 0.25 |
| MACD | 0.22 | -0.02 |
| Stochastic Oscillator | 83.62 | 42.14 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.